

# Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026

<https://marketpublishers.com/r/G991BD7B5E2FEN.html>

Date: January 2020

Pages: 1500

Price: US\$ 3,000.00 (Single User License)

ID: G991BD7B5E2FEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026' Report Highlight:

Global Gene Therapy Market Opportunity: > US\$ 8 Billion

Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials

Commercially Available Gene Therapies: 11

USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials

Cancer Accounts For 50% of Global Gene Therapy Trials

The potential of gene therapy approach to address the diseases that are unable to get treated with any other treatment is quickly becoming a reality and the approval of gene therapy products for the commercial use is seeking for a fascinating breakthrough over the other achievements that mankind has achieved over the decades. Gene therapy brings with it the promise of one-time treatment of the target that are underlying the genetic level. The therapy has brought several fascinating companies that are currently conducting research about the trending area of biotech. Gene therapy tends to bring an increase in the baby boomer generation compelled to grow and live longer.

The research report “Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026” is poised towards the current market trends followed by the therapy since its advent at international level and delivering a summarized information about the whole concept of the gene therapy in order to restore the gene functions by manipulating the genetic code present within the genome. The report discusses the current available gene therapy agents with their complete data regarding the dosage, sales and pricing compiled from multiple sources and from publications by companies that are thriving the market of gene therapy. The entire clinical and non-clinical framework along with the countries encompassed with the presence of agents is also discussed. The report highlights the need of such advanced technique and the entire huge breakthrough the technique is going through.

The whole arena of gene therapy came into limelight when the therapy treated the first patient having ADA-SCID. Since then, the fundamental benefits received from the therapy never got limited. The therapy has blessed the patients many agents with unique strategies and nonetheless many efforts made by the researchers are underway to get utilized against the diseases that have no other viable treatment. The therapy can alter the target DNA sequence by silencing, replacing or by manipulating the level of the substitute protein in order to restore the patient’s body against the target disease.

As there are various diseases that are associated with cancer, therefore the technology provides a potential treatment for the patient and it is expected that the therapy will provide deep insight about the genetic diseases and its treatment in future too. For the future, the gene therapy process is believed to be at a crucial position and will undoubtedly revolutionize the clinical, preclinical and technical techniques utilized in the laboratories. The editing of specific genes present in the pool of genome is considered as a groundbreaking discovery like the discovery of vaccines and antibiotics. It is just the matter of time that the technology will be categorized as a dominating one over the other available technologies.

Gene therapy has been designed such that it can provide relief to the patients with rare genetic disease with one approach i.e. manipulation at the genetic level. One approach of the technique gets investigated for a number of results which in-turn results in the approval of several gene therapy agents in a regulated way. In exchange, the therapy also entails for a cheap and one-time treatment- single injection or infusion when compared with the many years of expensive ongoing treatment.

The advent of the therapy for the well-being of the patients has definitely shifted the timings of the healthcare costs. The novel gene therapy agents anticipation in the

market has successfully determined the value of the gene therapy and its urgency. The value based research of the therapy has gained the interest of the clinicians and researchers ensuring the best of the benefits from the therapy. The comparative effectiveness and cost-effectiveness have inclined the dependency of the patients towards gene therapy while gaining excess commercial success in the global market.

## Contents

### **1. INTRODUCTION TO GENE THERAPY**

- 1.1 Gene Therapy: An Overview
- 1.2 History of Development

### **2. GENE THERAPY & ITS IMPACT ON GENETIC ALTERATIONS**

- 2.1 Gene Therapy as a Mastermind of Genetic Revolution
- 2.2 Manipulations at Molecular Level by Gene Therapy

### **3. WORKING MECHANISM OF GENE THERAPY**

- 3.1 Classification of Gene Therapy on the Basis of Cell Type
  - 3.1.1 Somatic Gene Therapy
  - 3.1.2 Germline Gene Therapy
- 3.2 Classification on the Basis of Gene Delivery Mechanism
  - 3.2.1 Ex-Vivo Delivery of the Gene
  - 3.2.2 In-Vivo Delivery of the Gene
- 3.3 Classification on the Basis of Gene Delivery Methods
  - 3.3.1 Viral Methods
  - 3.3.2 Non-Viral Methods
- 3.4 Classification on the Basis of End-Results
  - 3.4.1 Augmentation Gene Therapy
  - 3.4.2 Targeted Gene Therapy

### **4. MOLECULAR TOOLS AVAILABLE FOR GENE THERAPY**

- 4.1 Targeting Specific Loci with ZFN's
- 4.2 Introduction of TALEN's as a Gene Therapy Tool
- 4.3 Development of CRISPR to Mediate Precise Genome Editing

### **5. STRATEGIES OPTED BY GENE THERAPY**

- 5.1 Replacement of Defective Genes with Healthy Genes
- 5.2 Fixing Mutated Genes by Gene Therapy Molecular Tools
- 5.3 Gene Therapy Modifying the Diseased Cells & Making them Evident against Immune Cells

## **6. GENE THERAPY & THE JOURNEY OF CLINICAL TRIALS ASSOCIATED**

### 6.1 Trends Associated with Clinical Research & Trials

- 6.1.1 Clinical Trials Regarding Gene Therapy: Disease Analysis
- 6.1.2 Clinical Trials Regarding Gene Therapy: Vector Analysis
- 6.1.3 Clinical Studies Regarding Gene Therapy: Global Analysis
- 6.1.4 Clinical Trials Regarding Gene Therapy: Gene Type Analysis
- 6.1.5 Clinical Trials Regarding Gene Therapy: Current Status
- 6.1.6 Clinical Trials Regarding Gene Therapy: Gender Analysis
- 6.1.7 Clinical Trials Regarding Gene Therapy: Funding Analysis

## **7. APPROACH OF GENE THERAPY AGAINST CANCER**

- 7.1 Clinical Efficacy of Gene Therapy for Cancer Cells
- 7.2 Gendicine: A Wide Spectrum Anti-Cancer Gene Therapy Agent
- 7.3 Rixin-G for Osteosarcoma & Soft Tissue Sarcoma
- 7.4 Kymriah: A Breakthrough Gene Therapy Product for B-Cell Acute Lymphoblastic Leukemia
- 7.5 Yescarta: Gene Therapeutic Approach for B-Cell Lymphoma
- 7.6 Oncorine Approval by Shanghai Sunway Biotech Co. Ltd.
- 7.7 Gene Therapy Product Imlygic against Melanoma

## **8. GENE THERAPY FOR THE TREATMENT OF NEUROMUSCULAR DISEASES - SPINAL MUSCULAR ATROPHY & DUCHENNE MUSCULAR DYSTROPHY**

- 8.1 Clinical Approach of Gene Therapy for Duchenne Muscular Dystrophy
- 8.2 Clinical Approach of Gene Therapy for Spinal Muscular Atrophy
- 8.3 Spinraza - First Approved Gene Therapy Product for Spinal Muscular Atrophy
- 8.4 Zolgensma Treatment for Spinal Muscular Atrophy Patients
- 8.5 Eteplirsen – A New Hope for the Patients with Duchenne Muscular Dystrophy

## **9. FIRST TARGETED TREATMENT FOR RARE INHERITED RETINAL DYSTROPHY**

- 9.1 Clinical Efficacy of the Gene Therapy Products
- 9.2 Luxturna for the Treatment of RPE65 Mutation Associated Retinal Dystrophy

## **10. GENE THERAPY MEDIATED TREATMENT OF PERIPHERAL ARTERY DISEASE**

10.1 Clinical Interference for Cardiovascular Disorders Gene Therapy

10.2 Neovasculgen Gene Therapy in Cardiovascular Diseases

## **11. CORRECTING SEVERE COMBINED IMMUNODEFICIENCY – ADENOSINE DEAMINASE DEFICIENCY THROUGH GENE THERAPY**

11.1 Clinical Potential of Gene Therapy Therapeutic Approach

11.2 Strimvelis Benefits for Rare Disease: Adenosine Deaminase Deficiency– Severe Combined Immunodeficiency

## **12. SUCCESS OF GENE THERAPY OVER OTHER DISEASES**

## **13. AVAILABILITY & REVOLUTION OF GENE THERAPY DRUGS IN THE MARKET**

## **14. GENE THERAPY PRODUCTS DOSAGE & PRICE ANALYSIS**

14.1 Kymriah

14.2 Yescarta

14.3 Spinraza

14.4 Zolgensma

14.5 Luxturna

14.6 Strimvelis

14.7 Eteplirsen

14.8 Imlygic

## **15. GLOBAL GENE THERAPY CLINICAL TRIALS INSIGHT**

15.1 By Phase

15.2 By Country

15.3 By Formulation

15.4 By Company

15.5 By Target

15.6 By Indication

## **16. GLOBAL GENE THERAPY CLINICAL TRIALS BY COMPANY, INDICATION & PHASE**

16.1 Research

16.2 Preclinical

- 16.3 Clinical
- 16.4 Phase-0
- 16.5 Phase-I
- 16.6 Phase-I/II
- 16.7 Phase-II
- 16.8 Phase-II/III
- 16.9 Phase-III
- 16.10 Preregistration
- 16.11 Registered

## **17. MARKETED GENE THERAPY CLINICAL INSIGHT**

- 17.1 YESCARTA
- 17.2 Kymriah
- 17.3 ZOLGENSMA
- 17.4 Gendicine
- 17.5 IMLYGIC
- 17.6 Glybera
- 17.7 INVOSSA
- 17.8 LUXTURNA
- 17.9 Neovasculgen
- 17.10 Zalmoxis
- 17.11 Rixin-G

## **18. GLOBAL MARKET LANDSCAPE OF GENE THERAPY**

- 18.1 Gene Therapy Market Overview
- 18.2 Gene Therapy Market - Regional Analysis
  - 18.2.1 US
  - 18.2.2 Europe
  - 18.2.3 Japan
  - 18.2.4 China
  - 18.2.5 India
  - 18.2.6 South Korea
  - 18.2.7 Taiwan

## **19. MERGERS & COLLABORATIONS BETWEEN MAJOR KEY PLAYERS OF THE MARKET**

- 19.1 Axovant Gene Therapies & Yposkesi's Strategic Partnership
- 19.2 Lonza and DiNAQOR AG's Strategic Collaboration
- 19.3 US\$ 1 Million to AavantiBio for Gene Therapy Development in Freidreich's Ataxia
- 19.4 Actinium Pharmaceuticals Collaboration with UC Davis for HIV-Related Lymphoma for ACT Gene Therapy Program

## **20. GLOBAL GENE THERAPY MARKET DYNAMICS**

- 20.1 Factors Driving the Growth of Gene Therapy
  - 20.1.1 Gene Therapy Dominant over Growing Prevalence of Cancer
  - 20.1.2 Increased R&D Activities with Rising Investments
  - 20.1.3 Increasing General Awareness Concerning Gene Therapy
- 20.2 Challenges Overpowering the Technology
- 20.3 Future Opportunities for Gene Therapy

## **21. COMPETITIVE LANDSCAPE**

- 21.1 Novartis
- 21.2 Spark Therapeutics
- 21.3 BioGen
- 21.4 Sarepta Therapeutics
- 21.5 Kite Pharma
- 21.6 Amgen
- 21.7 Solid Biosciences Inc.
- 21.8 uniQure NV
- 21.9 MeiraGTX Holdings
- 21.10 Audentis Therapeutics
- 21.11 Regenxbio Inc.
- 21.12 Alnylam Pharmaceuticals
- 21.13 Arrowhead
- 21.14 SQZ Biotechnologies
- 21.15 Bluerock Therapeutics
- 21.16 Zydus Takeda
- 21.17 Intrexon Corporation
- 21.18 Celgene
- 21.19 Roche
- 21.20 Oxford Biomedica
- 21.21 Genethon
- 21.22 Sangamo Biosciences



21.23 Juno Therapeutics

21.24 Collectis

21.25 Autolus Therapeutics plc

21.26 icell Gene Therapeutics

21.27 Allogene Therapeutics

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Basic Gene Therapy Technique
- Figure 1-2: Milestones in Gene-Based Therapies
- Figure 2-1: Molecular Requirements for Conducting Gene Therapy
- Figure 2-2: Number of Protocols Approved for Gene Therapy, 1999 & 2015
- Figure 2-3: Global - Percentage of Gene Therapy Protocols at Different Phases
- Figure 3-1: General Procedure for Performing Gene Therapy
- Figure 3-2: Classification of Gene Therapy on the Basis of Working
- Figure 3-3: Differentiation of Gene Therapy on the Basis of Cell Type
- Figure 3-4: General Mechanism of Somatic Gene Therapy
- Figure 3-5: Areas of Somatic Gene Therapy Utilization
- Figure 3-6: Success Percentage of Somatic Gene Therapy in Different Diseases
- Figure 3-7: General Mechanism of Germline Gene Therapy
- Figure 3-8: Differentiation of Gene Therapy on the Basis of Gene Delivery Mechanisms
- Figure 3-9: Ex-Vivo Delivery Mechanism for Gene Therapy
- Figure 3-10: Methods for In-Vivo Delivery of the Gene Therapy
- Figure 3-11: Differentiation of Gene Therapy on the Basis of Gene Delivery Methods
- Figure 3-12: Viral Vectors for Gene Therapy
- Figure 3-13: General Mechanism of Virus Vectors for Gene Therapy
- Figure 3-14: Non-Viral Methods of Gene Delivery
- Figure 3-15: Ultrasound Irradiation Leading to Membrane Pores
- Figure 3-16: Types of Gene Therapy on the Basis of End-Results
- Figure 3-17: Strategies Opted by Targeted Gene Therapy
- Figure 4-1: Molecular Tools Available for Performing Gene Therapy
- Figure 4-2: CompoZr - Price of a Single Kit (US\$), January' 2019
- Figure 4-3: Domains of TALE & their Respective Functions
- Figure 4-4: Applications of CRISPR-Cas9 Gene Editing Technology
- Figure 5-1: Overall Strategy for Gene Alteration Played by Gene Therapy
- Figure 5-2: Gene Replacement Therapy
- Figure 5-3: Gene Therapy Molecular Tool Participation in Fixing Defective Genes
- Figure 5-4: Modification of Immune Cells with Gene Therapy
- Figure 6-1: Global - Gene Therapy Clinical Trials by Diseases (%), 2019
- Figure 6-2: Global - Number of Gene Therapy Clinical Trials by Diseases, 2020
- Figure 6-3: Global - Clinical Trials on Monogenic Diseases (%), 2004, 2007, 2012 & 2017
- Figure 6-4: Global - Vectors Used in Clinical Trials (%), 1989 - 2017

Figure 6-5: Global - Number of Gene Therapy Clinical Trials Approved, 2010 - 2018

Figure 6-6: Global - Types of Genes Transferred in Gene Therapy Clinical Trials (%), 2017

Figure 6-7: Global - Number of Different Types of Genes Transferred in Gene Therapy Clinical Trials, 2017

Figure 6-8: Global - Number of Gene Therapy Trials in Different Phases, January' 2020

Figure 6-9: Global - Number of the Gene Therapy Clinical Trials in Different Status, January'2020

Figure 6-10: Global – Status of Gene Therapy Clinical Trials (%), January'2020

Figure 6-11 : Global - Total Number of Active, Not Recruiting Gene Therapy Clinical Trials, January' 2020

Figure 6-12: Global - Active, Not Recruiting Gene Therapy Clinical Trials (%), January' 2020

Figure 6-13: Global - Total Number of Completed Gene Therapy Clinical Trials, January' 2020

Figure 6-14: Global - Completed Gene Therapy Clinical Trials (%), January' 2020

Figure 6-15: Global - Total Number of Terminated Gene Therapy Clinical Trials, January' 2020

Figure 6-16: Global - Terminated Gene Therapy Clinical Trials (%), January' 2020

Figure 6-17: Global - Total Number of Withdrawn Gene Therapy Clinical Trials, January' 2020

Figure 6-18: Global - Withdrawn Gene Therapy Clinical Trials (%), January' 2020

Figure 6-19: Global - Number of Clinical Trials with Male Participants, January'2020

Figure 6-20: Global - Clinical Trials with Male Participants (%), January'2020

Figure 6-21: Global - Number of Clinical Trials with Female Participants, January'2020

Figure 6-22: Global - Clinical Trials with Female Participants (%), January'2020

Figure 6-23: Global - Gene Therapy Clinical Trials Funding Status, January'2020

Figure 6-24: Global - Gene Therapy Clinical Trials Funding Status (%), January'2020

Figure 7-1: Oncolytic Viruses Used in Gene Therapy Clinical Trials for Cancer

Figure 7-2: In-Vivo & Ex-Vivo Approved Drugs for Cancer Gene Therapy

Figure 7-3: Strategies Adapted by Gene Therapy Products against Cancer Cells

Figure 7-4: Global - Kymriah - Clinical Trials Start & Estimated Completion Year, January' 2020

Figure 7-5: Global - Yescarta - Clinical Trials Start & Estimated Completion Year, January' 2020

Figure 7-6: Global - Imlygic - Active Clinical Trials Start & Estimated Completion Year, January' 2020

Figure 8-1: Global – Population of Children below 14 Years (%), 2018

Figure 8-2: Global - Cases of Spinal Muscular Atrophy Type I before Birth (%), 2017

Figure 8-3: Global - Cases of Spinal Muscular Atrophy Type III (%), January' 2020

Figure 8-4: Patients with Homozygous Deletion of SMN1 Gene (%), 2017

Figure 8-5: Global - Origin of Spinal Muscular Atrophy Patients (%), 2017

Figure 8-6: Global – Number of Patients of Spinal Muscular Atrophy from Different Origins, 2017

Figure 8-7: Europe – Distribution of Spinal Muscular Atrophy Patients (%), 2017

Figure 8-8: Europe – Distribution of Spinal Muscular Atrophy Patients, 2017

Figure 8-9: Europe – Spinal Muscular Atrophy Patient Population (%), 2017

Figure 8-10: Europe – Number of Spinal Muscular Atrophy Patients, 2017

Figure 8-11: Global – Distribution of Patients with Spinal Muscular Atrophy Subtypes (%), 2017

Figure 8-12: Global – Spinal Muscular Atrophy Patients by Gender (%), 2017

Figure 8-13: Global – Number of Spinal Muscular Atrophy Patients by Gender, 2017

Figure 8-14: Global – Distribution of Spinal Muscular Atrophy Patients by Age Group (%), 2017

Figure 8-15: Global – Number of Spinal Muscular Atrophy Patients by Age Group, 2017

Figure 8-16: Age of Development of Clinical Signs for Duchenne Muscular Dystrophy, 2020

Figure 8-17: Mutations Leading to the Development of Duchenne Muscular Dystrophy (%), 2019

Figure 8-18: Strategies by Gene Therapy for Duchenne Muscular Dystrophy

Figure 8-19: Global - Conducted Gene Therapy Clinical Trials for Duchenne Muscular Dystrophy, January' 2020

Figure 8-20: Gene Therapy Strategies for Spinal Muscular Atrophy

Figure 8-21: Global – Spinal Muscular Atrophy - Clinical Trials Start & Estimated Completion Year, January' 2020

Figure 8-22: Global - Spinraza – Active Clinical Trials for Spinal Muscular Atrophy Start & Estimated Completion Year, January' 2020

Figure 8-23: Global - Spinraza – Recruiting Clinical Trials for Spinal Muscular Atrophy Start & Estimated Completion Year, January' 2020

Figure 8-24: Global - Spinraza – Recruiting Clinical Trials for Spinal Muscular Atrophy II Start & Estimated Completion Year, January' 2020

Figure 8-25: Global - Spinraza – Recruiting Clinical Trial for Spinal Muscular Atrophy III Start & Estimated Completion Year, January' 2020

Figure 8-26: Global - Zolgensma - Active Clinical Trials for Spinal Muscular Atrophy Start & Estimated Completion Year, January' 2020

Figure 8-27: Global - Zolgensma - Recruiting Clinical Trial for Spinal Muscular Atrophy Start & Estimated Completion Year, January' 2020

Figure 8-28: Global - Zolgensma - Recruiting Clinical Trial for Spinal Muscular Atrophy I

Start & Estimated Completion Year, January' 2020

Figure 8-29: Global - Eteplirsen – Active Clinical Trial Starting & Estimated Completion Year for Duchenne Muscular Dystrophy, January' 2020

Figure 8-30: Global - Eteplirsen – Completed Gene Therapy Clinical Trials Starting & Completion Year for Duchenne Muscular Dystrophy, January'2020

Figure 9-1: Gene Therapy for Retinal Dystrophy Disorder

Figure 9-2: Global - Estimated Cases of Retinal Dystrophy (Million), January'2020

Figure 9-3: Total Genes Responsible for Causing Retinal Disorders

Figure 9-4: Completed Gene Therapy Clinical Trials for Retinal Dystrophy - Starting & Completion Year, January'2020

Figure 10-1: UK – Total Population with Heart Disease (Million), 2019

Figure 10-2: Global - Status of Gene Therapy Clinical Trials Conducted for Cardiovascular Diseases, January'2020

Figure 10-3: Global - Status of Gene Therapy Clinical Trials Conducted for Cardiovascular Diseases (%), January'2020

Figure 10-4: Therapeutic Genes for Cardiovascular Disorders Gene Therapy Approach

Figure 10-5: Global - Clinical Trials for Cardiovascular Diseases - Start & Estimated Completion Year, January' 2020

Figure 10-6: Global - Neovasculgen – Completed Clinical Trials, January' 2020

Figure 11-1: Global - Cases of Adenosine Deaminase Deficiency (%), January' 2020

Figure 11-2: Global - Early & Late Onset Adenosine Deaminase Deficiency Deficiency (%), January' 2020

Figure 11-3: Global - Adenosine Deaminase Deficiency Gene Therapy Clinical Trials Completion Years, 2020

Figure 11-4: Global - Starting & Completion Year of Completed Gene Therapy Clinical Trials for Adenosine Deaminase Deficiency, 2020

Figure 11-5: Global - Strimvelis – Ongoing Clinical Trial Expected Starting & Completion Year for Adenosine Deaminase Deficiency, January' 2020

Figure 13-1: Timeline of the Approved Gene Therapy Products

Figure 14-1: Kymriah – Dose for Acute Lymphoblastic Leukemia for Body Weight Less than 50 kg (CAR-T Cells Million/kg), January' 2020

Figure 14-2: Kymriah – Dose for Acute Lymphoblastic Leukemia for Body Weight above 50kg (CAR-T Cells Million/kg), January' 2020

Figure 14-3: Kymriah – Dose for Refractory or Relapsed Lymphoblastic Leukemia (CAR-T Cells Million/kg), January' 2020

Figure 14-4: Kymriah – Half Yearly Sales (US\$ Million), 2018

Figure 14-5: Global – Kymriah Quarterly Sales (US\$ Million), Q1- Q3, 2019

Figure 14-6: Global – Kymriah Sales (US\$ Million), Q1 – Q3, 2018 & 2019

Figure 14-7: Kymriah – Initial Approval Year by US FDA & EMA

Figure 14-8: Yescarta – Dose Strength for Lymphoma (CAR-T Cells Million/kg), January' 2020

Figure 14-9: Global – Yescarta Annual Sales (US\$ Million), 2017 & 2018

Figure 14-10: Global – Yescarta Quarterly Sales (US\$ Million), Q1 – Q4, 2018

Figure 14-11: Regional – Yescarta Quarterly Sales (US\$ Million), Q4, 2018

Figure 14-12: Global – Yescarta Quarterly Sales (US\$ Million), Q1 – Q3, 2019

Figure 14-13: Yescarta – Initial US FDA & EMA Approval Year

Figure 14-14: Spinraza – Treatment Course with the Required Dosage (mg/day), January' 2020

Figure 14-15: Spinraza – Price of 5 ml Vial & Price/ml Solution (US\$), January' 2020

Figure 14-16: Spinraza – Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), January' 2020

Figure 14-17: Global – Spinraza Quarterly Sales (US\$ Million), Q1 – Q4, 2018

Figure 14-18: Global – Spinraza Quarterly Sales (US\$ Million), Q1 – Q4, 2018 & 2019

Figure 14-19: Spinraza – Annual Sales – US v/s Row (US\$ Million), 2018

Figure 14-20: Spinraza – Annual Sales – US v/s Row (%), 2018

Figure 14-21: Spinraza – Initial US FDA & EMA Approval Year

Figure 14-22: Zolgensma – Concentration of Vector Genome per ml Available in the Kit of 5.5 & 8.3 ml (Trillion), January' 2020

Figure 14-23: Zolgensma – Available Dosing Pattern (Volume) per Body Weight of the Patient, January' 2020

Figure 14-24: Annual Treatment Cost - Zolgensma v/s Other Therapy (US\$ Million), 2019

Figure 14-25: Zolgensma – Initial US FDA & EMA Approval Year

Figure 14-26: Luxturna – Recommended Dose of the Drug (Vector Genomes Million), January' 2020

Figure 14-27: Luxturna – Dose Concentrations (Vector Genomes Million), January' 2020

Figure 14-28: Luxturna – Treatment Price for Single & Both Eyes (US\$ Million), January' 2020

Figure 14-29: Global – Luxturna Quarterly Sales (US\$ Million), Q1 – Q4, 2018

Figure 14-30: Global – Luxturna Quarterly Sales (US\$ Million), Q1, 2018 & 2019

Figure 14-31: Global – Luxturna Quarterly Sales (US\$ Million), Q2, 2018 & 2019

Figure 14-32: Global – Luxturna External Research & Development Expenses (US\$ Million), Q1, 2018 & 2019

Figure 14-33: Global – Luxturna External Research & Development Expenses (US\$ Million), Q2, 2018 & 2019

Figure 14-34: Luxturna – Initial US FDA & EMA Approval Year

Figure 14-35: Strimvelis – Minimum & Maximum Concentration (CD34+ Million)

Cells/ml), 2020

Figure 14-36: Stimvelis – Recommended Dose (CD34+ Million Cells/kg), 2020

Figure 14-37: Stimvelis – Research & Development Expenses (US\$ Million), 2017 & 2018

Figure 14-38: Stimvelis – Selling, General & Administrative Expenses (US\$ Million), 2017 & 2018

Figure 14-39: Stimvelis – Research & Development Expenses (US\$ Million), Q3, 2018 - 2019

Figure 14-40: Stimvelis – Selling, General & Administrative Expenses (US\$ Million), Q3, 2018 & 2019

Figure 14-41: Stimvelis – EMA Issue & Expiry Year

Figure 14-42: Eteplirsen – Average Recommended Dose of the Drug (mg/kg), January' 2020

Figure 14-43: Eteplirsen – Price of Intravenous Solution (US\$), January' 2020

Figure 14-44: Eteplirsen – Cost of Treatment (US\$), 2016

Figure 14-45: Global – Eteplirsen Quarterly Sale (US\$ Million), Q1 – Q4, 2018

Figure 14-46: Global – Eteplirsen Quarterly Sales (US\$ Million), Q2 – Q3, 2018 & 2019

Figure 14-47: Imlygic – Recommended Dose & Schedule for Treatment (pfu/ml), January' 2020

Figure 14-48: Imlygic – Price of Drug Injectable Suspension 1mpfu/ml (US\$), January' 2020

Figure 14-49: Imlygic – Price of Drug Injectable Suspension 100 mpfu/ml (US\$), January' 2020

Figure 14-50: Global – Imlygic Expected Total Sale (US\$ Million), 2016 & 2022

Figure 15-1: Global - Gene Therapy Clinical Trials by Phase (Number),2020 till 2026

Figure 15-2: Global - Gene Therapy Clinical Trials by Country (Number),2020 till 2026

Figure 15-3: Global - Gene Therapy Clinical Trials by Formulation (Number),2020 till 2026

Figure 15-4: Global - Gene Therapy Clinical Trials by Company (Number),2020 till 2026

Figure 15-5: Global - Gene Therapy Clinical Trials by Target (Number),2020 till 2026

Figure 15-6: Global - Gene Therapy Clinical Trials by Indication (Number),2020 till 2026

Figure 18-1: Factors Leading to Significant Growth of Gene Therapy Market

Figure 18-2: Global - Expected Gene Therapy Market Size (US\$ Million), 2018 - 2026

Figure 18-3: India – Patients with Diseases Treated by Gene Therapy, 2019

Figure 18-4: India – Patients with Diseases Treated by Gene Therapy (%), 2019

Figure 18-5: India – Minimum & Maximum Number of People with Rare Diseases, 2019

Figure 18-6: India – Minimum & Maximum Number of People with Rare Diseases (%), 2019

Figure 18-7: Korea – Total Number of New Cancer Cases & Cancer Deaths, 2019

Figure 18-8: Korea – Total Number of New Cancer Cases & Cancer Deaths, 2019

Figure 18-9: Korea – Number of Cancer Deaths v/s Total Population, 2019

Figure 20-1: Predicted Future of Gene Therapy



## I would like to order

Product name: Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/G991BD7B5E2FEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G991BD7B5E2FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970